Login to Your Account



Complix's Series B to Move Alphabodies into the Clinic

By Nuala Moran
Staff Writer

Wednesday, November 14, 2012
LONDON – Complix NV is in the thick of a €15 million to €20 million (US$19 million to $25 million) Series B fundraising, as it prepares to move the first of its intracellular-targeting Alphabodies into Phase I trials in 2013.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription